Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Report 2026

The hypertrophic cardiomyopathy (hcm) therapeutics market size has grown steadily in recent years. It will grow from $1.37 billion in 2025 to $1.41 billion in 2026 at a compound annual growth rate (CAGR) of 3.2%. The growth in the historic period can be attributed to improved awareness of inherited cardiomyopathies, widespread use of beta blockers and calcium channel blockers, increased availability of diagnostic imaging, rising prevalence of genetic cardiac disorders, hospital-based management of high-risk patients.

The hypertrophic cardiomyopathy (hcm) therapeutics market size is expected to see steady growth in the next few years. It will grow to $1.62 billion in 2030 at a compound annual growth rate (CAGR) of 3.6%. The growth in the forecast period can be attributed to growing adoption of novel myosin inhibitors, expansion of genetic screening programs, increasing use of implantable defibrillators, rising focus on personalized cardiology care, improving long-term disease management outcomes. Major trends in the forecast period include increasing adoption of targeted myosin inhibitors, growing focus on early diagnosis and risk stratification, rising use of implantable cardiac devices for sudden death prevention, expansion of combination drug and device-based therapy approaches, higher emphasis on long-term symptom management and quality of life.

The rising incidence of cardiovascular diseases (CVD) is expected to drive the growth of the hypertrophic cardiomyopathy (HCM) therapeutics market. Cardiovascular diseases are conditions that affect the heart or blood vessels, including heart irregularities such as atrial fibrillation, ventricular fibrillation, and atrioventricular block, which often require long-term monitoring. Therapeutic interventions for hypertrophic cardiomyopathy primarily aim to alleviate symptoms and prevent sudden cardiac death in high-risk patients. For example, in January 2024, the American Heart Association, a US-based non-profit organization, reported that the age-adjusted death rate from cardiovascular disease increased to 233.3 per 100,000 in 2024, representing a 4% rise from 224.4 per 100,000 in 2023. Consequently, the increasing prevalence of cardiovascular diseases is propelling the HCM therapeutics market.

Key companies in the HCM therapeutics market are focusing on small molecule allosteric cardiac myosin inhibitors, including selective myosin modulators, to gain a competitive edge. These agents help reduce excessive contractile force in the myocardium by limiting actin-myosin cross-bridge formation. For instance, in December 2024, Cytokinetics, a US-based biopharmaceutical company, received FDA acceptance of its New Drug Application for aficamten, a next-generation myosin inhibitor. The drug demonstrated significant improvements in peak VO₂, reductions in outflow tract gradients, and a favorable safety profile in the pivotal SEQUOIA HCM Phase III trial. This approach provides a disease-modifying alternative to conventional symptom-relief therapies, though it involves regulatory complexity, as evidenced by the submission of a risk evaluation and mitigation strategy (REMS) with the NDA.

In November 2023, Merck Sharp & Dohme, a US-based pharmaceutical company, acquired Caraway Therapeutics, Inc. for an undisclosed amount. Through this acquisition, Merck aims to leverage its research and development expertise to advance innovative therapies for genetically defined neurodegenerative and rare diseases, with the goal of developing disease-modifying treatments that can significantly alter disease progression. Caraway Therapeutics is a US-based biopharmaceutical company specializing in small-molecule therapeutics for rare and neurodegenerative diseases.

Major companies operating in the hypertrophic cardiomyopathy (hcm) therapeutics market are Merck & Co. Inc., Pfizer Inc., Sanofi SA, Teva Pharmaceutical Industries Ltd., Novartis AG, AstraZeneca plc, Gilead Sciences Inc., Bayer AG, Correvio Pharma Corp., Advanz Pharma Corp., Lupin Limited, Boston Scientific Corporation, Bristol-Myers Squibb Company, Johnson & Johnson, Medtronic plc, Cardiome Pharma Corp., Cytokinetics Inc., Daiichi Sankyo Company Limited, GlaxoSmithKline plc., HUYA Bioscience International LLC, Ionis Pharmaceuticals Inc., Kowa Company Ltd., Luitpold Pharmaceuticals Inc., Menarini Group, Mitsubishi Tanabe Pharma Corporation, Nippon Shinyaku Co. Ltd., Otsuka Holdings Co. Ltd., Servier Laboratories.

North America was the largest region in the hypertrophic cardiomyopathy (HCM) therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the hypertrophic cardiomyopathy (HCM) therapeutics market report during the forecast period. The regions covered in the hypertrophic cardiomyopathy (hcm) therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the hypertrophic cardiomyopathy (hcm) therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have affected the hypertrophic cardiomyopathy therapeutics market by increasing costs of imported active pharmaceutical ingredients, cardiac devices, and implantable defibrillator components, impacting treatment affordability and procurement timelines. These effects are more significant in regions dependent on imported medical devices and specialty drugs, including parts of Asia-Pacific and Latin America. At the same time, tariffs are encouraging local manufacturing, regional device assembly, and diversification of supply chains, supporting long-term market resilience and access to advanced HCM therapies.

The hypertrophic cardiomyopathy (hcm) therapeutics market research report is one of a series of new reports that provides hypertrophic cardiomyopathy (hcm) therapeutics market statistics, including hypertrophic cardiomyopathy (hcm) therapeutics industry global market size, regional shares, competitors with a hypertrophic cardiomyopathy (hcm) therapeutics market share, detailed hypertrophic cardiomyopathy (hcm) therapeutics market segments, market trends and opportunities, and any further data you may need to thrive in the hypertrophic cardiomyopathy (hcm) therapeutics industry. This hypertrophic cardiomyopathy (hcm) therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Hypertrophic cardiomyopathy (HCM) therapeutics refers to treatments for a condition in which the heart muscle becomes abnormally thickened, impairing the heart’s ability to pump blood effectively. These therapeutics aim to alleviate symptoms and prevent sudden cardiac death in high-risk patients.

The primary drug categories in the HCM therapeutics market include antiarrhythmic agents, anticoagulants, beta-adrenergic blockers, calcium channel blockers, and other medications. Antiarrhythmic agents are used to manage abnormal heart rhythms or arrhythmias. The associated medical devices include defibrillators, pacemakers, and other supportive devices, which are primarily utilized in hospitals and clinical settings.

The hypertrophic cardiomyopathy (HCM) therapeutics market consists of revenues earned by entities by provide progressive disease management, physical therapy (PT), and occupational therapy. The market value includes the value of related goods sold by the service provider or included within the service offering. The hypertrophic cardiomyopathy (HCM) therapeutics market also consists of sales of disopyramide, wearable heart monitoring devices, and cardiac rhythm management (CRM) devices which are used in providing hypertrophic cardiomyopathy (HCM) therapeutics services. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.